News
ATHE
4.660
-0.21%
-0.010
Alterity study shows QSM MRI tracks iron buildup, severity in multiple system atrophy
PUBT · 9h ago
Alterity Therapeutics presents MSA program update at medical conferences
PUBT · 3d ago
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Barchart · 4d ago
Weekly Report: what happened at ATHE last week (0427-0501)?
Weekly Report · 05/04 09:05
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Alterity Therapeutics (ATHE) and Moderna (MRNA)
TipRanks · 05/01 17:30
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Barchart · 04/30 06:25
Alterity Therapeutics director Ann Michelle Cunningham files initial beneficial ownership statement
PUBT · 04/30 00:05
Alterity Therapeutics announces upcoming shareholder meeting
PUBT · 04/29 12:13
Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study
NASDAQ · 04/27 12:16
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
TipRanks · 04/27 11:42
Alterity Therapeutics Receives Positive FDA Feedback Following A Type C Meeting Regarding Its Planned Phase 3 Development Program For ATH434 In Multiple System Atrophy, A Rare, Rapidly Progressive Neurodegenerative Disease With No Approved Disease-Modifying Treatments
Benzinga · 04/27 11:28
ALTERITY THERAPEUTICS LTD - END-OF-PHASE 2 FDA MEETING REMAINS SCHEDULED FOR MID-2026
Reuters · 04/27 11:24
Alterity says FDA backs ATH434 Phase 3 manufacturing plans for multiple system atrophy trial
PUBT · 04/27 10:22
Weekly Report: what happened at ATHE last week (0420-0424)?
Weekly Report · 04/27 09:05
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Barchart · 04/27 06:25
Alterity Therapeutics presents new data analyses from ATH434 trial
TipRanks · 04/22 11:44
Alerity Therapeutics Announces Presentation Of New Data Analyses From The Phase 2 Trial Of ATH434, Demonstrating Clinical Efficacy In Patients With Multiple System Atrophy At The American Academy of Neurology Annual Meeting
Benzinga · 04/22 11:30
Alterity says Phase 2 ATH434 slows MSA decline on MuSyCA at week 52
PUBT · 04/22 10:17
Weekly Report: what happened at ATHE last week (0413-0417)?
Weekly Report · 04/20 09:05
More
Webull provides a variety of real-time ATHE stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.